AZITRA INC. NEW Aktie Logo
US05479L2034

AZITRA INC. NEW Aktie

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

    Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International Convention BRANFORD, Conn. , June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.» Mehr auf prnewswire.com


  • Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

    BRANFORD, Conn. , June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts.» Mehr auf prnewswire.com


  • Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

    BRANFORD, Conn. , May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte AZITRA INC. NEW Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 2,84 Mrd
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen2,84 Mrd104.268,94%
EBITDA2,87 Mrd109.689,58%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+3,78 Mio
Anzahl Aktien
17,23 Mio
52 Wochen-Hoch/Tief
+10,23 - +0,19
DividendenNein
Beta
-1,78
KGV (PE Ratio)
0,00
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,00
KUV (PS Ratio)
+0,59

Unternehmensprofil

Name
AZITRA INC. NEW Aktie
CEO
Francisco D. Salva
Mitarbeiter12
🍪

Parqet nutzt Cookies.Erfahre Mehr